…
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Astellas Pharma Inc is a Japan-based global pharmaceutical company focused on discovering, developing and commercializing therapies primarily in oncology, urology, transplantation and other specialty areas. Its long-term growth may be driven by new oncology indications and launches, pipeline advances including regenerative and gene therapies, and revenues from established products across developed and emerging markets, which could support steady cash flow and scale.
Primary investment risks include patent expirations on key products, regulatory and clinical trial setbacks, competitive pressures and pricing or reimbursement headwinds that could impair revenues.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | 399298.15M | 31237.00M | 24969.00M | 132361.00M | 156886.00M |
| Minority interest | -40.00M | - | - | - | - |
| Net income | 309116.85M | 50747.00M | 17045.00M | 98714.00M | 124086.00M |
| Selling general administrative | 860312.00M | 843032.00M | 740110.00M | 630272.00M | 548840.00M |
| Gross profit | 1691018.18M | 1563117.00M | 1311187.00M | 1230266.00M | 1043154.00M |
| Reconciled depreciation | 194594.00M | 199132.00M | 157840.00M | 105738.00M | 79684.00M |
| Ebit | 445009.08M | 48914.00M | 36974.00M | 140928.00M | 137601.00M |
| Ebitda | 651338.63M | 248046.00M | 194814.00M | 246666.00M | 217285.00M |
| Depreciation and amortization | 206329.55M | 199132.00M | 157840.00M | 105738.00M | 79684.00M |
| Operating income | 445009.08M | 41039.00M | 25518.00M | 133029.00M | 155686.00M |
| Other operating expenses | 1823249.18M | 1871284.00M | 1578154.00M | 1387062.00M | 1165200.00M |
| Interest expense | 14920.65M | 17677.00M | 12005.00M | 8779.00M | 4949.00M |
| Tax provision | 85013.00M | -19510.00M | 7924.00M | 33647.00M | 32800.00M |
| Interest income | 8026.00M | 7874.00M | 11455.00M | 8110.00M | 6149.00M |
| Net interest income | -6046.00M | -9803.00M | -550.00M | -669.00M | 1200.00M |
| Income tax expense | 90139.95M | -19510.00M | 7924.00M | 33647.00M | 32800.00M |
| Total revenue | 2268258.26M | 1912323.00M | 1603672.00M | 1518619.00M | 1296163.00M |
| Total operating expenses | 1246009.10M | 1522078.00M | 1285669.00M | 1098709.00M | 912191.00M |
| Cost of revenue | 577240.07M | 349206.00M | 292485.00M | 288353.00M | 253009.00M |
| Total other income expense net | -45710.93M | -9802.00M | -549.00M | -99291.00M | -61259.00M |
| Net income from continuing ops | 291574.00M | 50747.00M | 17045.00M | 98714.00M | 124086.00M |
| Net income applicable to common shares | - | - | - | - | 124086.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 3582512.86M | 3339544.00M | 3569603.00M | 2456518.00M | 2332395.00M |
| Intangible assets | 1001255.86M | 1123714.00M | 1453824.00M | 562496.00M | 623431.00M |
| Other current assets | 47747.19M | 53250.00M | 46536.00M | 32428.00M | 28998.00M |
| Total liab | 1743688.01M | 1826289.00M | 1973615.00M | 948564.00M | 872087.00M |
| Total stockholder equity | 1838824.85M | 1513255.00M | 1595988.00M | 1507954.00M | 1460308.00M |
| Other current liab | 776048.32M | 572688.00M | 589739.00M | 585798.00M | 556672.00M |
| Common stock | 103447.73M | 103001.00M | 103001.00M | 103001.00M | 103001.00M |
| Capital stock | 103001.00M | 103001.00M | 103001.00M | 103001.00M | 103001.00M |
| Retained earnings | 906751.75M | 740939.00M | 809400.00M | 908158.00M | 944261.00M |
| Other liab | - | - | - | 106852.00M | 128986.00M |
| Good will | 443088.45M | 415207.00M | 418694.00M | 328411.00M | 303030.00M |
| Other assets | - | - | - | 84170.00M | 72330.00M |
| Cash | 282826.37M | 188372.00M | 335687.00M | 376840.00M | 315986.00M |
| Total current liabilities | 1223685.41M | 1061610.00M | 1285725.00M | 726034.00M | 687411.00M |
| Current deferred revenue | - | - | 38515.00M | - | - |
| Net debt | -35807.63M | 643054.00M | 584329.00M | -376840.00M | -315986.00M |
| Short term debt | 247018.73M | 266533.00M | 472278.00M | - | - |
| Short long term debt | 245952.00M | 266533.00M | 472278.00M | - | - |
| Short long term debt total | 247018.73M | 831426.00M | 920016.00M | - | - |
| Other stockholder equity | 152717.50M | 669315.00M | 683587.00M | -1011159.00M | -1047262.00M |
| Property plant equipment | - | - | - | 286459.00M | 269044.00M |
| Total current assets | 1428090.12M | 1201349.00M | 1194730.00M | 1049954.00M | 923354.00M |
| Net tangible assets | - | - | - | - | 533847.00M |
| Short term investments | 9572.00M | 29941.00M | 28784.00M | 19784.00M | 21297.00M |
| Net receivables | 765066.89M | 632525.00M | 534985.00M | 446516.00M | 404001.00M |
| Long term debt | 320000.00M | 564893.00M | 447738.00M | - | - |
| Inventory | 332449.66M | 297261.00M | 248738.00M | 174386.00M | 153072.00M |
| Accounts payable | 200618.36M | 187840.00M | 185193.00M | 140236.00M | 130739.00M |
| Accumulated other comprehensive income | 675907.87M | - | 533301.00M | - | - |
| Non currrent assets other | 43595.26M | 1.00M | 45595.00M | 1.00M | -1.00M |
| Non current assets total | 2154422.74M | 2138195.00M | 2374873.00M | 1406564.00M | 1409041.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | 0.00M | -89419.00M | -845802.00M | -84500.00M | -62413.00M |
| Change to liabilities | - | - | - | 0.00M | -10101.00M |
| Total cashflows from investing activities | -77174.51M | -89419.00M | -845802.00M | - | -62413.00M |
| Net borrowings | -267418.00M | -88522.00M | 771233.00M | -15000.00M | -60000.00M |
| Total cash from financing activities | -429190.35M | -261367.00M | 614060.00M | -195623.00M | -216298.00M |
| Change to operating activities | - | - | - | - | -16639.00M |
| Net income | 309116.85M | 31237.00M | 17045.00M | 132361.00M | 156886.00M |
| Change in cash | 81555.28M | -147315.00M | -41153.00M | 60854.00M | -10142.00M |
| Begin period cash flow | 201271.09M | 335687.00M | 376840.00M | 315986.00M | 326128.00M |
| End period cash flow | 282826.37M | 188372.00M | 335687.00M | 376840.00M | 315986.00M |
| Total cash from operating activities | 600400.38M | 194512.00M | 172475.00M | 327767.00M | 257444.00M |
| Depreciation | 1291.34M | 199132.00M | 157840.00M | 105738.00M | 79684.00M |
| Other cashflows from investing activities | 12575.25M | -65336.00M | -22772.00M | - | -10017.00M |
| Dividends paid | 144306.84M | 128993.00M | 116653.00M | -100355.00M | -85236.00M |
| Change to inventory | -17196.07M | -50225.00M | -60036.00M | -7086.00M | 24058.00M |
| Change to account receivables | -67641.28M | -104735.00M | -55948.00M | -4849.00M | -8001.00M |
| Sale purchase of stock | -774.02M | -6960.00M | -10735.00M | -60556.00M | -50717.00M |
| Other cashflows from financing activities | -197383.73M | -36892.00M | -29785.00M | -3217.00M | -2530.00M |
| Change to netincome | - | - | - | 15688.00M | 31557.00M |
| Capital expenditures | 61204.15M | 57330.00M | 82497.00M | 88541.00M | 76448.00M |
| Change in working capital | 29036.53M | -166369.00M | -86518.00M | -24209.00M | 5956.00M |
| Other non cash items | 262247.00M | 130512.00M | 84108.00M | 113877.00M | 14918.00M |
| Free cash flow | 539196.23M | 137182.00M | 89978.00M | 239226.00M | 180996.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALPMY Astellas Pharma Inc |
-0.03 0.17% |
17.12 | 13.89 | 12.82 | 0.01 | 2.09 | 2.08 | 7.59 |
| LLY Eli Lilly and Company |
-1.20 0.09% |
1347.11 | 38.16 | 24.15 | 12.72 | 29.95 | 13.31 | 25.43 |
| JNJ Johnson & Johnson |
5.53 2.07% |
272.67 | 30.96 | 20.79 | 6.58 | 7.55 | 6.84 | 19.73 |
| ABBV AbbVie Inc |
-0.20 0.07% |
286.20 | 74.10 | 16.21 | 7.22 | 50.46 | 8.18 | 27.04 |
| RHHVF Roche Holding AG Participation |
- -% |
480.00 | 24.16 | 16.53 | 5.71 | 8.88 | 4.94 | 14.76 |
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenji Yasukawa Ph.D. | Pres, CEO & Chairman | 1960 |
| Mr. Naoki Okamura BSc | Exec. VP, Chief Strategy Officer & Representative Director | NA |
| Minoru Kikuoka | CFO & Sr. Managing Exec. Officer | NA |
| Nobue Yasuda | Gen. Mang. of Fin. & Accounting Department | NA |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Sr. Managing Exec. Officer | NA |
| Ms. Catherine B. Levitt | Gen. Counsel | NA |
| Mr. Katsuyoshi Sugita | Chief People Officer and Chief Ethics & Compliance Officer | NA |
| Mr. Stig Ogata | VP of Corp. Communications | NA |
| Ms. Collette Taylor | Sr. VP of HR | 1963 |
| Chihiro Yokota | Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.